logo
Giant, flightless bird is next target for de-extinction company Colossal Biosciences

Giant, flightless bird is next target for de-extinction company Colossal Biosciences

Yahoo09-07-2025
A species of huge, flightless bird that once inhabited New Zealand disappeared around 600 years ago, shortly after human settlers first arrived on the country's two main islands. Now, a Texas-based biotech company says it has a plan to bring it back.
Genetic engineering startup Colossal Biosciences has added the South Island giant moa — a powerful, long-necked species that stood 10 feet (3 meters) tall and may have kicked in self-defense — to a fast-expanding list of animals it wants to resurrect by genetically modifying their closest living relatives.
The company stirred widespread excitement, as well as controversy, when it announced the birth of what it described as three dire wolf pups in April. Colossal scientists said they had resurrected the canine predator last seen 10,000 years ago by using ancient DNA, cloning and gene-editing technology to alter the genetic make-up of the gray wolf, in a process the company calls de-extinction. Similar efforts to bring back the woolly mammoth, the dodo and the thylacine, better known as the Tasmanian tiger, are also underway.
To restore the moa, Colossal Biosciences announced Tuesday it would collaborate with New Zealand's Ngāi Tahu Research Centre, an institution based at the University of Canterbury in Christchurch, New Zealand, that was founded to support the Ngāi Tahu, the main Māori tribe of the southern region of New Zealand.
The project would initially involve recovering and analyzing ancient DNA from nine moa species to understand how the giant moa (Dinornis robustus) differed from living and extinct relatives in order to decode its unique genetic makeup, according to a company statement.
'There is so much knowledge that will be unlocked and shared on the journey to bring back the iconic moa,' Ben Lamm, CEO and co-founder of Colossal Biosciences, said in the statement. For example, the company said, researching the genomes of all moa species would be 'valuable for informing conservation efforts and understanding the role of climate change and human activity in biodiversity loss.'
Colossal, which has raised at least $435 million since it was founded by Lamm and Harvard University geneticist George Church in 2021, has committed 'a large investment' to New Zealand, the company said without giving further details. Peter Jackson, the New Zealand-born 'Lord of the Rings' director, who is one of a number of high-profile investors in the company, is also involved with the project. He has one of the largest private collections of moa bones, according to the Associated Press.
Scott MacDougall-Shackleton, cofounder and director of the Advanced Facility for Avian Research at Western University in London, Ontario, said that because the moa went extinct in the past few hundred years there were extensive bones, egg shell fragments, and even feathers that could be studied. He was not involved in the research.
'The primary explanation for their extinction is overhunting and habitat change following the arrival of Polynesian peoples to the island,' he explained via email.
'Prior to this they had very few predators,' he said. 'This is a pattern for flightless birds on islands that have very little defence against hunting or predation (like dodos).'
The idea of reviving a species like this was 'intellectually interesting, but really should be a low priority,' MacDougall-Shackleton said. 'If we are concerned about island bird conservation there are hundreds of threatened and critically endangered species in New Zealand, Hawaii and other Pacific islands that need conservation resources more urgently.'
As part of the project, Colossal said it would undertake ecological restoration projects in New Zealand, focusing on rehabilitating potential moa habitats while supporting existing native species.
Many scientists argue that while Colossal's researchers are advancing the field of genetic engineering, it's not truly possible to resurrect an extinct animal — any attempt could only create a genetically modified, hybrid species. Suggesting that extinction can be reversed through technology risks undermining the urgency of conserving existing species and ecosystems, critics say.
Lamm, Colossal's CEO, told CNN's Fareed Zakaria last month that the biotechnology Colossal develops will be used to help rescue animals on the brink of extinction as well as those that have already disappeared. For example, he said, Colossal has produced two litters of cloned red wolves, the most critically endangered wolf species, using a new, less invasive approach to cloning developed during the dire wolf research.
'I think that we could have a scalable de-extinction system that isn't going to replace conservation, but it is kind of that additional backup that I think we need, especially in these dire cases,' Lamm said.
Scott Edwards, a professor of organismic and evolutionary biology and curator of ornithology at the Museum of Comparative Zoology at Harvard University, said he was excited by the project although the techniques necessary to bring back the giant moa would be different to the dire wolf, because birds develop in an egg, making the process more challenging, he said.
'It's important that science reaches for the stars and, you know, I do understand the ethical concerns with bringing (these birds back) especially if there's no place for them,' Edwards, who was not involved in the project, said. 'But if it works it will impress upon humanity just how much we've lost.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Biogen sees potential in combining Alzheimer's and obesity drugs
Biogen sees potential in combining Alzheimer's and obesity drugs

Boston Globe

time11 hours ago

  • Boston Globe

Biogen sees potential in combining Alzheimer's and obesity drugs

Advertisement Biogen's looking to the growth of its Alzheimer's drug Leqembi to offset the decline of its multiple sclerosis franchise, which is facing competition from cheaper generic drugs. Biogen's new Alzheimer's drug is already facing competition from Eli Lilly & Co.'s Alzheimer's drug, which was approved in the US last year and has since captured around 30 percent of the market, according to analysts. Other companies are also circling. Novo is carrying out clinical trials to assess whether the main ingredient in diabetes drug Ozempic and weight-loss shot Wegovy might help people with early Alzheimer's disease. Research suggests that the weight-loss drug could slow Alzheimer's progression by impacting inflammation and vascular health. Results of Novo's late-stage trial are expected later this year. Advertisement Viehbacher noted that being overweight is a risk factor for Alzheimer's. He cautioned the Novo study 'is a fairly risky proposition,' adding that 'most of the experts we're talking to are not convinced that it will work.' 'It's logical if you have a weight-loss drug that you can see some benefit, but it's actually pretty hard to move the needle on the cognitive side,' Viehbacher added. Alzheimer's drug development has been riddled with failures, even when drugs looked promising in early studies. Leqembi is a partnership between Cambridge, Massachusetts-based Biogen and Japanese drugmaker Eisai Co. Biogen makes the active ingredient for Leqembi in Switzerland. The company then ships it to North Carolina, where it gets made into a product. President Donald Trump recently put a 39 percent tariff on imports from Switzerland. It's unclear whether this would impact Biogen's drug. Still, Viehbacher said the company has the ability to start producing the substance used to make Leqembi in North Carolina for the US market, while continuing to make it in Switzerland for outside the US. He said the company always intended to use its North Carolina facilities to make Leqembi and the potential move was not a direct response to Trump's tariff threats. Last month, Biogen announced it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research Triangle Park.

Livestock operations tied to worsened air pollution, study finds
Livestock operations tied to worsened air pollution, study finds

E&E News

time11 hours ago

  • E&E News

Livestock operations tied to worsened air pollution, study finds

Thousands of large-scale cattle- and hog-raising operations are disproportionately located near marginalized communities, according to a new study that ties those 'factory farms' to sharply higher levels of harmful air pollution. The study published Tuesday in the journal Communications Earth & Environment offers what the authors describe as a first-ever rundown of the distribution of almost 16,000 animal feeding operations (AFOs) across the United States. They found that about one-quarter of those operations are clustered in just 30 counties in states like California, Texas and Nebraska. To varying degrees, nearby residents are more likely to be Latino and lack high school diplomas or health insurance. Advertisement Levels of fine particulate matter pollution were 28 percent higher in census tracts around cattle AFOs and 11 percent higher in areas near hog farms compared with places lacking those operations.

Ai2 unveils MolmoAct: Open-source robotics system reasons in 3D and adjusts on the fly
Ai2 unveils MolmoAct: Open-source robotics system reasons in 3D and adjusts on the fly

Geek Wire

time13 hours ago

  • Geek Wire

Ai2 unveils MolmoAct: Open-source robotics system reasons in 3D and adjusts on the fly

Jiafei Duan, Ai2 researcher, shows MolmoAct controlling a robotic arm. (GeekWire Photo / Todd Bishop) The Allen Institute for AI released a new AI robotics system that uses novel approaches to help robots navigate messy real-world environments, while making all of the model's code, data, and training methods publicly available under open-source principles. The system, called MolmoAct, converts 2D images into 3D visualizations, previews its movements before acting, and lets human operators adjust those actions in real time. It differs from existing robotics models that often work as opaque black boxes, trained on proprietary datasets. Ai2 expects the system to be used by robotics researchers, companies, and developers as a foundation for building robots that can operate in unstructured environments such as homes, warehouses, and disaster response scenes. In demos last week at Ai2's new headquarters north of Seattle's Lake Union, researchers showed MolmoAct interpreting natural language commands to direct a robotic arm to pick up household objects, such as cups and plush toys, and move them to specific locations. Researchers described it as part of AI2's broader efforts to create a comprehensive set of open-source AI tools and technologies. The Seattle-based research institute was founded in 2014 by the late Microsoft co-founder Paul Allen, and is funded in part by his estate. Ai2's flagship OLMo large language model is a fully transparent alternative to proprietary systems, with openly available training data, code, and model weights, designed to support research and public accountability in AI development. The institute's projects are moving in 'one big direction' — toward a unified AI model 'that can do reasoning and language, that can understand images, videos, that can control a robot, and that can make sense of space and actions,' said Ranjay Krishna, Ai2's research lead for computer vision, and a University of Washington Allen School assistant professor. MolmoAct builds on AI2's Molmo multimodal AI model — which can understand and describe images — by adding the ability to reason in 3D and direct robot actions.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store